- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
ROVI
MCE
Week ended 07 Aug 2026
Weekly Investor Report
Laboratorios Farmaceuticos Rovi, S.A. · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
58.35 EUR
-0.4%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -15.5% below the Trend Line and sits at 15.6% of its 52-week range. The latest completed week returned -0.4%, after a 6.0% four-week move. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
36
out of 100
Latest Close
58.35 EUR
7 Aug 2026
1W Return
-0.4%
latest completed week
4W Return
6.0%
short-term follow-through
12W Return
-1.0%
quarterly tape
Trend Breadth
73.1%
38 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.4%
Latest completed week; four-week move 6.0%.
Indicator stack
40/40
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
7 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -15.5% below the Trend Line and sits at 15.6% of its 52-week range. The latest completed week returned -0.4%, after a 6.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0312-week average 0.34
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 6.0% over four weeks, -1.0% over 12 weeks, and 8.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year38
Trend breadth73.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.72Latest activity-pressure read.
Pressure change42.7%Four-week change in activity pressure.
Leadership-23.56Latest relative-leadership reading.
RS change10.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 7 relevant articles.
0 positive · 6 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-32.7%Distance below the 52-week high.
13-week volatility3.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+8.6%Week of 24 Jul.
Worst week-20.8%Week of 8 May.
Latest week-0.4%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains7
Flat weeks0
Modest losses11
Sharp losses4
Recent vol3.2%13-week weekly-return volatility.
Base vol5.0%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.4% / -3.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorES Healthcare
4-week rank5 / 14
Group average3.0%
Trend breadth35.7%
Trend35.7%active weekly trend signals
MD28.6%positive activity pressure
RS21.4%positive relative leadership
Four-week leaders
IndustryES Drug Manufacturers - Specialty & Generic
4-week rank1 / 5
Group average0.9%
Trend breadth40.0%
Trend40.0%active weekly trend signals
MD0.0%positive activity pressure
RS20.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape33/100
Trend, activity pressure, participation, and risk combine to a 33/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.03; No reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 7 relevant articles.
ETFs Investing in Laboratorios Farmaceuticos Rovi, S.A. Stocks Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 58.35 EUR | -0.4% | 69.04 EUR | 64.05 EUR | -0.72 | -23.56 | 437.1K | Off |
| 31 Jul 2026 | 58.60 EUR | -0.3% | 69.38 EUR | 63.97 EUR | -0.87 | -22.00 | 468.7K | Off |
| 24 Jul 2026 | 58.80 EUR | 8.6% | 69.54 EUR | 63.88 EUR | -1.01 | -21.27 | 1.2M | Off |
| 17 Jul 2026 | 54.15 EUR | -1.6% | 69.67 EUR | 63.77 EUR | -1.20 | -26.44 | 654.0K | Off |
| 10 Jul 2026 | 55.04 EUR | -1.6% | 69.93 EUR | 63.69 EUR | -1.26 | -26.23 | 768.1K | Off |
| 3 Jul 2026 | 55.93 EUR | -2.9% | 70.17 EUR | 63.58 EUR | -1.36 | -27.20 | 226.4K | Off |
| 26 Jun 2026 | 57.60 EUR | 1.0% | 70.30 EUR | 63.47 EUR | -1.42 | -23.80 | 84.5K | Off |
| 19 Jun 2026 | 57.01 EUR | -1.4% | 70.36 EUR | 63.36 EUR | -1.41 | -24.61 | 91.1K | Off |
| 12 Jun 2026 | 57.79 EUR | -1.7% | 70.39 EUR | 63.24 EUR | -1.38 | -21.57 | 82.3K | Off |
| 5 Jun 2026 | 58.80 EUR | -0.8% | 70.43 EUR | 63.13 EUR | -1.32 | -18.73 | 86.5K | Off |
| 29 May 2026 | 59.30 EUR | 0.4% | 70.30 EUR | 63.01 EUR | -1.15 | -18.36 | 702.9K | Off |
| 22 May 2026 | 59.05 EUR | 0.2% | 70.36 EUR | 62.88 EUR | -0.94 | -17.22 | 698.8K | Off |
| 15 May 2026 | 58.95 EUR | -6.2% | 70.54 EUR | 62.77 EUR | -0.60 | -15.79 | 980.2K | Off |
| 8 May 2026 | 62.85 EUR | -20.8% | 70.57 EUR | 62.66 EUR | -0.08 | -11.71 | 2.0M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.